Zurcher Kantonalbank Zurich Cantonalbank Boosts Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 10.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,909 shares of the medical device company’s stock after buying an additional 1,403 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Tandem Diabetes Care were worth $441,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TNDM. SG Americas Securities LLC lifted its position in shares of Tandem Diabetes Care by 70.9% during the third quarter. SG Americas Securities LLC now owns 23,510 shares of the medical device company’s stock worth $488,000 after purchasing an additional 9,751 shares during the last quarter. Commonwealth Equity Services LLC lifted its holdings in Tandem Diabetes Care by 10.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock worth $205,000 after buying an additional 908 shares during the last quarter. Raymond James & Associates grew its position in shares of Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock worth $836,000 after acquiring an additional 737 shares in the last quarter. Chicago Capital LLC increased its holdings in shares of Tandem Diabetes Care by 699.8% in the 3rd quarter. Chicago Capital LLC now owns 904,410 shares of the medical device company’s stock valued at $18,785,000 after acquiring an additional 791,336 shares during the last quarter. Finally, JB Capital LLC raised its position in shares of Tandem Diabetes Care by 63.1% during the 3rd quarter. JB Capital LLC now owns 16,252 shares of the medical device company’s stock valued at $338,000 after acquiring an additional 6,288 shares in the last quarter.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $44.72 on Friday. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91. The business’s 50-day moving average price is $32.29 and its 200 day moving average price is $26.08. Tandem Diabetes Care, Inc. has a 52-week low of $13.82 and a 52-week high of $47.00. The firm has a market cap of $2.89 billion, a P/E ratio of -13.00 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. The business had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. As a group, sell-side analysts predict that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TNDM has been the subject of several recent research reports. Stifel Nicolaus boosted their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, April 23rd. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. Wells Fargo & Company raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $21.00 to $45.00 in a report on Monday, April 29th. SVB Leerink raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $34.00 to $45.00 in a research report on Thursday, April 25th. Finally, Citigroup boosted their target price on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.45.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.